01689-A: Increasing the Effectiveness of Radiation Therapy in Treatment of Mast Cell Tumors

Grant Status: Closed

Grant Amount: $12,921.54
Keijiro Shiomitsu, DVM; Louisiana State University
April 1, 2012 - March 31, 2016

Sponsor(s): Boston Terrier Club of America

Breed(s): Boxer
Research Program Area: Oncology
Donate to Support this Research Program Area


Canine mast cell tumors are the most common cutaneous malignant tumors in dogs. Histologic grades, I, II, and III, provide very useful information because they are indicative of a patient's prognosis. Treatment options depend on negative prognostic factors, but in general surgery and radiation therapy are very effective. Chemotherapy could be applied if the patient has either systemic disease or a grade III mast cell tumor. The most commonly used chemotherapy drugs for mast cell tumors are CCNU and vinblastine. A new therapeutic agent, Palladia, targets a receptor on mast cell tumors called c-kit (CD117). Dr. Shiomitsu will investigate if Palladia can enhance the radiosensitivity of canine mast cell tumor cells in vitro and determine the mechanism of radiosensitization when it occurs. Radiosensitization by Palladia may be able to improve local tumor control, and hopefully prolong survival time for radiation oncology patients.


None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2018 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software